Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxford / AstraZeneca vaccine has today been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65.

Syringe going into a vaccine vial

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website.

The authorisation of the Chadox1-nCoV19 vaccine manufactured by AstraZeneca, and the Serum Institute of India (SII), enables global access to the vaccine during the pandemic.

Andrew Pollard, Professor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford vaccine trial, said:

‘At the University of Oxford, we are all so pleased by today’s announcement because the emergency use listing from WHO is a critical piece in the path to global access to the Chadox1-nCoV19 vaccine and our mission for vaccines to protect the vulnerable, whoever they are, and wherever they live.’

The process assesses the safety, quality and efficacy of COVID-19 vaccines, as well as other, more pragmatic considerations, such as cold chain requirements, and follows on from WHO’s Strategic Advisory Group of Experts on Immunization recommendation for the use of the vaccine in all adult age groups.

Read the full story on the University of Oxford website.

Similar stories

300 companies created by the University of Oxford

The University of Oxford has reached the milestone of creating 300 companies based on research and ideas from students, staff and alumni.

What’s your sound barrier? New study finds nearly one in five people in the UK find everyday sounds intolerable

Researchers from King’s College London and University of Oxford have shown that 18.4 per cent of the general UK population report that certain sounds, such as loud chewing, and repetitive sniffing, cause a significant problem in their lives. The condition is known as misophonia.

Misophonia: nearly one in five UK adults have the condition causing extreme reactions to certain sounds

Many of us have sounds that we find to be annoying. But for some people, certain sounds actually trigger extreme reactions.

Any type of hormonal contraceptive may increase risk of breast cancer

An analysis of data by researchers at the Nuffield Department of Population Health’s Cancer Epidemiology Unit has shown that use of progestogen-only hormonal contraceptives is associated with a 20-30% higher risk of breast cancer. The results are published in PLOS Medicine.

Viewing self-harm images on the internet and in social media usually causes harm, according to new review

Clinical researchers have reviewed the international research evidence regarding the impact of viewing images of self-harm on the internet and in social media.